Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• ExploreTech is an exploration technology company that originated at Stanford University, developing an approach to exploration planning that’s more efficient than traditional methods.
• ExploreTech’s probabilistic modeling and drill planning solution pinpoints targets below cover, achieving the same or better drilling results with fewer boreholes.
• Recently, Canamera Energy Metals has engaged ExploreTech to deploy this technology at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

As the world becomes more reliant on technology and makes the shift to clean-energy, the critical metals they rely on are becoming more and more sought after. This increased demand requires a more efficient and effective approach to discover and delineate minerals.

ExploreTech, a Stanford-originated exploration technology company, has developed amore efficient approach to exploration planning than what’s currently available, and demonstrated this technology on over 15 partner projects. The company has shown excellent results, intersecting its predicted targets at every project drilled so far. 

In preparation for its drilling campaign, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), a rare earth and critical metals exploration company, has engaged ExploreTech to conduct an independent data review and drill optimization at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

ExploreTech will deploy the company’s proprietary ExploreTech Engine, which is a computing platform that runs probabilistic modeling workflows, to optimize capital spend and refine the depth extent and geometry of the four flagship priority target areas at the Project, which are Goldfinch, Blue Jay, Blackbird, and Starling. 

It’ll also optimize drill collar placement and deliver a ranked, phased drilling sequence in support of Canamera’s recommended 1,500 meter, nine-hole helicopter-supported diamond drilling program.

Speaking about the engagement, Brad Brodeur, CEO of Canamera Energy Metals, said that “Engaging ExploreTech brings a quantitative, evidence-weighted layer to our drill targeting that complements the technical work already completed by the Independent Qualified Person and the Project’s prior operators. ExploreTech’s track record speaks for itself, and partnering with them is consistent with our broader commitment to deploying best-in-class tools across the portfolio to maximize the return on every metre of drilling.”

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• TechForce Robotics has partnered with NUWA Robotics and Foxconn to support the transition from pilot deployments to scalable commercial production and enterprise rollout
• The company combines AI-driven robotics, enterprise automation infrastructure, and Robotics-as-a-Service capabilities to address growing demand for fleet-scale automation solutions
• Recent expansion into pharmaceutical automation broadens TechForce’s addressable market while reinforcing its strategy of building a scalable robotics commercialization ecosystem

TechForce Robotics, Inc. (“TechForce”), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is extending the boundaries of service robotics commercialization, moving its AI-powered automation platforms from pilot deployments into industrial-scale, revenue-generating fleet systems. Reputed for developing autonomous service robots created for logistics, hospitality, healthcare, and commercial settings, the company is now advancing toward full-scale commercialization through integrated manufacturing and deployment partnerships, opening the door to a new era of scalable Robotics-as-a-Service Provider (“RaaSP”) adoption across enterprise markets (ibn.fm/KnktY).

A key milestone in that transition came through a recently announced strategic supply agreement with NUWA Robotics and Foxconn (Hon Hai Precision Industry Co., Ltd.), one of the world’s largest electronics manufacturers. The agreement marks an important evolution from development-stage robotics into commercial production and deployment (ibn.fm/rXOWN). According to the company, the collaboration establishes “a comprehensive framework for the development, manufacturing, and commercialization of next-generation robotic systems” and is intended to position TechForce to scale production efficiently through a globally recognized manufacturing ecosystem.

The structure reflects a deliberate commercialization strategy that separates commercial vision, engineering execution, and manufacturing scale. Under the agreement, TechForce defines product strategy, market requirements, and customer deployment objectives while retaining ownership of its intellectual property. NUWA Robotics contributes engineering development and systems integration expertise, while Foxconn provides manufacturing, testing, assembly, and global fulfillment capabilities. Together, the framework is designed to address one of the most significant challenges facing the robotics industry, converting successful pilot deployments into enterprise-scale rollouts.

TechForce Robotics operates at the intersection of AI-driven automation, deployment infrastructure, service robotics engineering, and emerging pharmaceutical applications. The company is building an ecosystem designed to reduce friction in enterprise adoption by delivering autonomous systems that can be deployed, managed, and scaled across commercial environments. Its platform supports operational functions such as material transport, internal logistics, and service automation within high-traffic facilities.

Beyond manufacturing scale, the company has continued expanding its deployment infrastructure through strategic partnerships aimed at accelerating real-world adoption (ibn.fm/YAEU9). As highlighted in its recent announcement TechForce’s commercial pipeline collaborations intended to support Robotics-as-a-Service growth across hospitality, logistics and healthcare.

The company’s commercialization strategy is also expanding into pharmaceutical and life sciences applications. Through a recently announced initiative focused on pharmaceutical automation, TechForce is applying its robotics expertise to regulated drug development and manufacturing environments, where automation can improve operational efficiency, consistency, and compliance. The move demonstrates the flexibility of the company’s platform architecture and highlights management’s intent to pursue opportunities beyond traditional service robotics markets.

Taken together, these developments illustrate a broader strategy of blending deployment infrastructure with scalable manufacturing capacity, addressing both ends of the commercialization pipeline. As enterprise customers seek fully supported automation solutions rather than isolated pilot programs, companies capable of delivering production-ready systems at scale may be positioned to capture a larger share of growth.

TechForce’s approach is built upon years of real-world deployments across hospitality and service environments, where its systems have been tested, refined, and optimized under operational conditions. The company’s platform combines proprietary autonomous navigation technology, AI-powered fleet management software, and modular robotic systems designed for complex environments

Core systems include Its modular autonomous robot, TIM-E (“Timmy”), which transports items across large, complex facilities using interchangeable attachments to handle logistics such as inventory delivery, linen movement and waste collection, allowing operations to scale without replacing core systems. Alongside this, BIM-E (Beverages in Motion – Everywhere) automates beverage dispensing in high-traffic environments, ensuring consistent pours, reducing waste and maintaining speed during peak demand. 

For investors, the significance of these developments extends beyond the underlying technology. The combination of Foxconn’s manufacturing scale, NUWA’s engineering expertise, expanding deployment partnerships, and entry into pharmaceutical automation suggests that TechForce may be entering a phase where commercialization execution becomes increasingly important to the investment story. Rather than simply developing robotic systems, the company is assembling the infrastructure required to support larger-scale deployments across multiple industries.

For more information, visit the company’s website at TechForceRobotics.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

• Earth Science Tech Inc. (OTC: ETST) recently reported year-end financial results for the fiscal year ending March 31, 2026
• Earth Science Tech acquires, manages, and operates companies in pharmaceuticals, real estate, telemedicine, healthcare services, and other industries.
• Results include increases in revenue, gross profit, net income, and total assets.

Earth Science Tech (OTC: ETST), a strategic holding company that acquires and manages a diverse portfolio of businesses, recently announced the financial results for the full fiscal year that ended on March 31, 2026 (https://ibn.fm/xRoIz).

The reported results include:

• An 8% revenue increase compared to the year ended March 31, 2025, with revenue rising to $35.7 million from $33.1 million.
• A 5% rise in gross profit, as it climbed to $25.5 million from $24.3 million.
• An 11% increase in net income, as it rose to $3.6 million from $3.3 million.
• Total assets that rose by 27%, going to $9 million from $7.1 million.

Earth Science Tech CEO, Giorgio R. Saumat, said that “Our fiscal 2026 results reflect the meaningful progress we have made over the last several years to build a business that is durable, self-sustaining and positioned for long-term growth.” He added that “These results are driven by the work we have done to better integrate the patient experience across our platform, from telemedicine to pharmacy to fulfillment. By owning more of that process, we serve patients effectively while building a stronger and more profitable business.”

Earth Science Tech builds value by acquiring and managing companies and operates a diverse portfolio of revenue-generating businesses. The company’s core exposure is in acquiring and scaling cash-flowing assets across healthcare, pharmaceutical compounding, and telemedicine. The goal is controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling, can drive durable growth, with an emphasis on capital discipline, execution, and long-term value creation.

Earth Science Tech currently has a large portfolio which includes compound pharmacies RxCompoundStore and Mister Meds, telehealth companies MyOnlineConsultation and DOConsultations, as well as Las Villas Health Care, which is both an online telehealth platform and brick-and-mortar clinic. It also operates real estate development firm Avenvi, plus Magnechef, a direct-to-consumer retail brand.

The team at Earth Science Tech is led by CEO and Chairman of the Board, Giorgio R. Saumat. Saumat is an investor and entrepreneur with more than 20 years of experience in investing, operating, and consulting for private businesses and investors. It also features a number of other seasoned professionals with a wealth of experience in areas like finance, technology, business development, and strategic development.

For more information, visit the Earth Science Tech website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• Zacks Investment Research noted progress in the company’s gamification business and potential growth catalysts despite broader industry challenges.
• A key factor was the company’s unique technology, plus improved first-quarter 2026 financial results, including significantly reduced operating losses and positive operating cash flow.
• Versus Systems offers a unique technology platform combining interactive gaming, real-world rewards, and advertising experiences designed to increase customer engagement and loyalty.
• Versus’ Winfinite and Filter Fan Cam products provide opportunities across digital marketing, sports, entertainment, and live-event environments.
• The company’s relationship with ASPIS and the potential extension of its technology licensing agreement may provide future recurring revenue opportunities.

Versus Systems (NASDAQ: VS), a leading provider of gamification and audience engagement technology, has received new attention from the investment community following the initiation of research coverage by Zacks Investment Research, which highlighted the company’s recent operational progress and future growth opportunities (https://ibn.fm/POyah).

The research assessment comes as Versus continues to refine its business model and expand its audience engagement technology during a period when companies across marketing, sports, and media industries are seeking more interactive methods of reaching consumers.

Zacks highlighted how Versus has made notable progress in strengthening its financial position. The company’s first-quarter 2026 results showed a significant reduction in operating losses, driven primarily by lower selling, general, and administrative expenses as well as continued cost management initiatives.

The quarter also marked a meaningful operational milestone as the company generated positive operating cash flow, reflecting improved working-capital management and stronger cash collections. The financial improvements may reduce dependence on external financing while supporting continued investment in technology development.

Zacks also identified several factors that may contribute to future growth. These include the company’s ongoing discussions regarding a potential extension of its technology licensing relationship with ASPIS, which could provide additional recurring revenue and improve visibility into future cash flows.

At the core of Versus’ business is a patented business-to-business engagement platform designed to transform passive audiences into active participants through interactive games, competitions, and real-world rewards. 

The company operates through two primary platforms: Winfinite and Filter Fan Cam (“FFC”). Both products address a common challenge facing marketers and content creators, maintaining consumer attention in an increasingly crowded digital environment.

Winfinite allows brands, agencies, and media companies to create customized interactive campaigns without the time and expense typically associated with building proprietary gaming experiences. The platform includes a collection of adaptable games, including trivia, sports-themed challenges, arcade-style activities, and promotional contests.

Participants can receive a range of rewards depending on the campaign, including discounts, digital incentives, merchandise, and other prizes. By connecting participation with tangible rewards, Versus seeks to create stronger engagement between brands and their audiences. The company’s technology has already reached a substantial user base. According to company materials, more than 10 million consumers have participated in campaigns utilizing Versus technology across sports, entertainment, and corporate environments. 

A key advantage of the platform is its ability to operate across multiple digital and physical channels. Campaigns can be deployed through websites, mobile applications, streaming platforms, broadcasts, and live events, allowing organizations to create consistent engagement strategies across customer touchpoints.

Versus has also expanded its presence in live entertainment through Filter Fan Cam, an augmented reality-based fan engagement solution. The technology incorporates facial tracking and digital effects to create interactive experiences that can appear on venue displays and broadcast feeds. The platform has been used at professional sporting events, including activations involving Major League Baseball’s Texas Rangers at Globe Life Field. For sports teams and venue operators, these experiences can create additional sponsorship opportunities while encouraging deeper fan participation.

The company’s ability to manage reward-based campaigns internationally represents another component of its technology offering. According to corporate information, Versus has distributed rewards across multiple countries, including the United States, United Kingdom, India, China, and Mexico.

This capability is particularly relevant as brands increasingly pursue global digital campaigns that require compliance with different promotional and contest regulations. By providing infrastructure for rewards administration, Versus enables organizations to focus on campaign design and customer interaction.

Versus Systems continues to develop additional products and features intended to broaden its ecosystem. Initiatives such as Play Winfinite aim to expand social and competitive gaming experiences by allowing users to participate with friends and communities while earning rewards.

For more information, visit the company’s website at www.VersusSystems.com.

NOTE TO INVESTORS: The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI

• VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
• The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
• VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
• The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”),  and other antibody-based formats.
• VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://ibn.fm/ZcS3w).

The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results provide initial evidence supporting the company’s approach of using dual-targeted mechanisms to activate potent therapeutic payloads only when both components reach the same tumor cell.

Traditional antibody-drug conjugates have transformed parts of cancer treatment by allowing targeted delivery of highly potent therapies. However, a continuing challenge within the field is the unintended exposure of healthy tissue to toxic payloads, which can limit dosing and contribute to adverse effects.

VERAXA’s BiTAC strategy, short for Bi-targeted Tumor-Associated Cytotoxicity, seeks to address this challenge by separating a therapeutic system into two complementary molecules. Individually, these molecules are designed to remain inactive. Therapeutic activity occurs only when both components bind to the intended cancer cell, creating an “AND-gated” approach aimed at improving tumor specificity.

According to the company, this architecture is being applied across two major technology platforms: BiTAC-ADCs and BiTAC-TCEs. The BiTAC-TCE platform was previously presented at the American Association for Cancer Research (“AACR”) Annual Meeting in 2026, where early preclinical data showed selective activity against cells expressing both target markers while reducing effects on cells carrying only one of the targets. Together, the BiTAC-ADC and BiTAC-TCE programs represent VERAXA’s strategy of developing conditionally activated therapies that may offer a broader therapeutic window compared with conventional approaches.

The company entered the public markets in June 2026 following the completion of its business combination with Voyager Acquisition Corp., beginning trading on the NASDAQ Capital Market under the ticker symbol VRXA. The listing provides VERAXA with greater access to capital markets as it advances its pipeline and evaluates future collaboration opportunities.

Beyond its BiTAC programs, VERAXA is developing a broader portfolio of antibody-based therapeutics focused on oncology. The company’s pipeline includes additional mono- and bispecific ADC programs, and other engineered therapeutic formats.

Its most advanced clinical-stage program, VX-A901, is a monoclonal antibody targeting FLT3 for the treatment of acute myeloid leukemia (“AML”). The therapy is designed to stimulate antibody-dependent cellular cytotoxicity, helping immune cells recognize and attack cancer cells. Early Phase I data indicated that the treatment was well tolerated among heavily pre-treated AML patients and showed initial signs of anti-tumor activity. As VERAXA increases its emphasis on solid tumor applications and BiTAC-based modalities, it intends to seek partners for the future development and commercialization of VX-A901.

The company’s research strategy reflects broader trends within the oncology industry, where pharmaceutical developers are increasingly investing in therapies that can improve targeting precision and reduce damage to healthy tissue. ADCs and bispecific antibodies have become important areas of research because they combine the specificity of antibodies with powerful therapeutics. 

Market forecasts indicate substantial growth opportunities in these sectors. According to Grand View Research, the global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is expected to reach about $32.11 billion by 2033, driven by increasing demand for targeted cancer treatments (https://ibn.fm/9L2vF). The market for bispecific antibodies is also projected to expand significantly over the next decade, supported by continued advances in immuno-oncology and precision medicine.

VERAXA traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), a research institution recognized for contributions to molecular biology and biotechnology. The company has built its development platform around proprietary antibody engineering technologies, biorthogonal click chemistry, and tumor-selective activation strategies designed to create more precise cancer therapeutics.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment
• Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability
• Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies

For decades, chemotherapy has carried a basic trade-off. The same drugs that kill cancer cells can also damage healthy tissue, leading to toxicity that can limit dosing, interrupt treatment, and reduce quality of life. Nanomedicine emerged as a strategy to change how a drug distributes throughout the body. By packaging the drug in nanoscale carriers, these formulations keep more drug in circulation long enough to accumulate in tumors, while reducing unnecessary exposure in healthy tissue Early enthusiasm gave way to skepticism as many experimental formulations failed to translate from animal models into clinical products. Now the field appears to be turning a corner, and a growing group of developers is working to define what the next generation of cancer nanomedicine looks like.

A Field Emerging from Skepticism

A 2025 review of clinical cancer nanomedicines published in the Journal of Controlled Release describes a field moving beyond what its authors characterize as a long trough of disillusionment. More than 20 nanomedicine formulations have now reached clinical use.

These products improve the therapeutic index of the drugs they carry, increasing the gap between therapeutic benefit and unwanted toxicity by altering how treatments distribute throughout the body. In doing so, they have measurably improved patient quality of life during treatment.

The review draws a distinction that matters for newer programs. Earlier generations of nanomedicines primarily made existing drugs more tolerable by reducing side effects. The generation now advancing aims to go further, using nanoparticle engineering to enable therapeutic effects that would not be possible with the free drug alone. That shift, from reducing harm to actively improving performance, provides the backdrop for a new wave of oncology development programs.

Where Onco-Innovations Fits

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a Canadian oncology company developing inhibitors of Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. Blocking PNKP is designed to leave cancer cells unable to repair damage caused by radiation and chemotherapy while also exploiting synthetic lethality in tumors carrying specific gene expression deficiencies.

PNKP inhibition represents an emerging class within the broader DNA Damage Response field, a category that generated more than $7 billion in sales in 2025 and continues expanding beyond established PARP inhibitors.

The company’s lead candidate, ONC010, sits squarely within the newer-generation nanomedicine model. It combines A83B4C63, a small-molecule inhibitor of PNKP, with a proprietary polymer nanodelivery system designed to encapsulate and transport the drug. In animal studies, the formulation slowed tumor growth, demonstrated favorable pharmacokinetics and low observed toxicity, and increased sensitivity to radiation and certain chemotherapies.

Why the Delivery Platform Matters

DNA Damage Response inhibitors have a challenging history. Several promising candidates have struggled with off-target toxicity or poor solubility that complicated dosing and distribution. Onco’s nanoparticle approach is designed to address those specific obstacles. A nanodelivery platform is not a cosmetic add-on in this context; it is a key part of the therapeutic design. The nanoparticle formulation helps solubilize and carry a small-molecule inhibitor that would otherwise be difficult to administer. By extending circulation time, concentrating the drug at the tumor site, and limiting exposure to healthy tissue, the delivery system is intended to widen the gap between therapeutic effect and toxicity, the central objective that has driven decades of nanomedicine development.

The company’s approach also aligns with broader trends identified in the clinical nanomedicine literature, where researchers increasingly view advanced delivery systems not simply as tools for reducing side effects, but as platforms capable of improving therapeutic performance.

A Key Manufacturing Partnership

Recent activity points to a growing focus on the scale-up and analytical framework that next-generation nanomedicines require. In June, Onco signed a non-binding letter of intent with Nanosoft Polymers, a North Carolina polymer company, to negotiate support for scaled polymer synthesis process development, analytical characterization, and formulation optimization activities.

Nanosoft is led by Dr. Xiaobing Xiong, who trained under Dr. Afsaneh Lavasanifar; both are co-inventors of Onco’s proprietary nanoparticle delivery technology. Days earlier, Onco reported producing approximately 952 grams of a key ONC010 precursor at kilogram scale through its collaboration with Dalton Pharma Services, setting the stage for the next phase of its manufacturing program. 

Building Toward the Clinic 

The history of cancer nanomedicine is a reminder that scientific promises and clinical reality do not always move in lockstep, and the field’s renewed momentum does not guarantee the success of any individual program. What it does suggest is that the questions now facing developers such as Onco-Innovations, surrounding delivery, formulation, scalability, and reproducibility, are increasingly becoming the right questions to ask.

As ONC010 advances toward first-in-human studies, the program reflects a broader shift underway across cancer nanomedicine, one focused not only on reducing drug toxicity but also on improving therapeutic performance. Whether that promise ultimately translates into clinical success remains to be seen, but the direction of the field is becoming increasingly clear.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• Beeline’s AI-enabled underwriting and customer acquisition tools are designed to reduce friction in mortgage approvals, particularly for gig-economy borrowers.
• Shares of Beeline Holdings, Inc. are set to join the Russell Microcap Index effective June 29, increasing visibility among institutional investors.
• The company’s first-quarter 2026 revenue more than doubled year over year to $2.7 million, while loan originations rose to $85.6 million.
• Management is targeting younger real estate investors alongside older homeowners seeking access to home equity without refinancing.
• The company continues investing in automation and adjacent software capabilities as it pursues a broader housing finance technology strategy.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to home ownership, was added as a member of the Russell Microcap Index, marking a notable milestone for the digital mortgage company as it attempts to scale its technology-driven lending platform during one of the most challenging housing finance environments in years.

The inclusion, effective June 29 following the annual Russell indexes reconstitution, places Beeline among a group of small-cap companies tracked by institutional investors and index-linked funds. According to FTSE Russell, approximately $12.2 trillion in assets are benchmarked against Russell US indexes. In a May 26 announcement, Chief Executive Officer Nick Liuzza said the company expects the addition to improve trading liquidity and broaden investor exposure to the business (https://ibn.fm/DeBYM).

Beeline has spent the last several years positioning itself as a technology-focused alternative to traditional mortgage originators. Through its subsidiary, Beeline Loans Inc., the company offers conventional mortgages alongside non-qualified mortgage products tailored to borrowers who may not fit standard underwriting models. The company’s strategy increasingly centers on automation, artificial intelligence and digital self-service tools designed to reduce approval timelines and simplify the financing process. Beeline says its platform can close loans in roughly 14 to 21 days, materially below broader industry averages.

During first-quarter 2026, Beeline reported revenue of $2.7 million, more than double the comparable period a year earlier. Loan originations increased to $85.6 million across 288 loans, up from $39.8 million and 128 loans in the prior-year quarter. The company’s recent operating results arrive at a time when many mortgage lenders continue grappling with elevated interest rates, muted refinancing demand and affordability pressures that have weighed heavily on housing activity nationwide.

Rather than chasing overall origination volume, management says the company is focusing on products with stronger economics. During Beeline’s quarterly earnings call, Liuzza emphasized that the company is prioritizing profitability and operational efficiency amid continued uncertainty surrounding inflation and capital markets. “We are leaning into the parts of the business that already work,” Liuzza said during the call. A major part of that strategy involves expanding Beeline’s presence in the Non-QM lending market, including debt-service coverage ratio loans and bank-statement products frequently used by self-employed borrowers and property investors.

The emphasis reflects broader demographic shifts reshaping the housing market. Younger borrowers, particularly millennials and members of Generation Z, continue facing significant barriers to homeownership. According to reporting by National Mortgage Professional, only 26.1% of Gen Z consumers and 54.9% of millennials owned homes in 2024, with mortgage qualification standards remaining a major obstacle for many applicants.

Beeline is attempting to address that gap through AI-assisted underwriting technology that can provide borrowers with rapid qualification assessments. The company says its digital tools can determine eligibility with roughly 90% certainty in as little as seven or eight minutes. The platform is also increasingly oriented toward younger consumers purchasing investment properties rather than only primary residences. Management argues that real estate investing may represent a more accessible path to wealth creation for borrowers navigating affordability constraints in traditional housing markets.

Chief Operating Officer Jess Kennedy said Beeline’s internally developed AI systems are helping improve conversion rates and operational efficiency. The company’s chatbot, known as Bob, has reportedly increased lead-to-lock conversion rates by approximately 8% when interacting with prospective borrowers online. Meanwhile, Beeline’s self-service mortgage workflow produced a 131% increase in application-to-lock pull-through during early deployment phases, according to company disclosures.

At the same time, Beeline is also targeting older homeowners through a separate equity-access platform called BeelineEquity. The product is designed to help homeowners monetize accumulated home equity without refinancing existing low-interest mortgages, an increasingly relevant issue in a higher-rate environment where many homeowners remain reluctant to replace mortgages originated during the ultra-low-rate period of 2020 and 2021.

Unlike conventional mortgage lending, BeelineEquity operates primarily as a fee-based business. The company says the product generates approximately 3.5% of transaction value in fees while also producing ancillary title revenue averaging around $1,500 per transaction. Management has emphasized that the structure carries no balance-sheet lending exposure.

Beeline also continues investing in adjacent software and automation capabilities. The company maintains a minority stake in MagicBlocks, an AI-focused sales platform supporting portions of Beeline’s internal infrastructure. During the latest earnings call, management disclosed that the software platform recently onboarded several major lenders, including one top-10 institution.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• Greenland Mines’ flagship Skaergaard Project hosts an NI 43-101 Mineral Resource estimate containing 11.4 million ounces PdEq in the Indicated category and 14.1 million ounces PdEq in the Inferred category.
• The pending acquisition of the Sarfartoq Project would add an advanced rare earth asset with a historical resource estimate, extensive drilling history and exposure to magnet rare earth elements including neodymium and praseodymium.
• The company’s relationship with Neo Performance Materials includes an offtake arrangement covering up to 60% of future Sarfartoq production, subject to completion of the acquisition and future project development.
• Greenland Mines is pursuing a North Atlantic critical minerals strategy that includes resource development in Greenland and potential downstream processing and logistics initiatives in Iceland.
• Greenland Mines’ strategic investment in AnorTech provides exposure to sustainable alumina, high purity alumina and related midstream processing opportunities that complement the company’s broader critical minerals strategy.

Greenland Mines (NASDAQ: GRML) is focused on the exploration and development of mineral assets in Greenland. Through its mining division, the company is advancing the Skaergaard Project in southeast Greenland while also pursuing the acquisition of the Sarfartoq rare earth project in southwest Greenland. Together, these assets provide exposure to precious metals, critical metals and rare earth elements within a jurisdiction that has attracted growing interest as governments and industries seek to diversify strategic mineral supply chains.

The company’s strategy centers on building a North Atlantic critical minerals platform that links resource development in Greenland with downstream processing, logistics infrastructure and industrial markets in Europe and North America. In June 2026, Greenland Mines expanded that strategy through a strategic investment in AnorTech Inc., providing exposure to sustainable alumina, high purity alumina and related industrial materials opportunities in Greenland. In addition to advancing its mineral assets, Greenland Mines has established relationships and initiatives designed to support future project development, including environmental studies, metallurgical work, infrastructure planning and downstream processing opportunities.

Greenland Mines also maintains a biotechnology division focused on developing therapies for neurodegenerative and age-related disorders. Supported by an experienced team spanning mining, geology, biotechnology and capital markets, the company is pursuing opportunities across both natural resources and life sciences.

The company is headquartered in Charlotte, North Carolina.

Mining

Greenland Mines’ mining division is centered on advancing the Skaergaard Project while pursuing the acquisition and development of the Sarfartoq rare earth project. The company has also made a strategic investment in AnorTech Inc., a Greenland-focused resource and technology company advancing sustainable alumina and high purity alumina opportunities. Together, these initiatives form the foundation of Greenland Mines’ North Atlantic critical minerals strategy.

Skaergaard Project

The Skaergaard Project is Greenland Mines’ flagship mineral asset located in southeast Greenland. The project hosts a stratiform palladium-gold-platinum deposit within the Skaergaard Intrusion and, according to the project’s NI 43-101 Technical Report effective Nov. 22, 2022, contains an Indicated Mineral Resource of 11.4 million ounces palladium equivalent (“PdEq”) within 159 million tonnes grading 2.23 g/t PdEq and an Inferred Mineral Resource of 14.1 million ounces PdEq within 205 million tonnes grading 2.14 g/t PdEq. Greenland Mines reports that approximately $30 million has been invested in the project since the 1990s, including approximately 45,000 meters of diamond drilling and channel sampling.

Greenland Mines controls three mineral exploration licenses covering approximately 877 square kilometers at Skaergaard and is advancing environmental, metallurgical and technical studies to support future development. The company has stated plans to pursue additional drilling, resource expansion and evaluation of potential critical-metal byproducts while also exploring downstream processing opportunities through initiatives in Iceland, including agreements related to the Helguvík industrial area that support its broader North Atlantic critical minerals strategy.

Sarfartoq Project

In May 2026, Greenland Mines entered into a definitive agreement to acquire Neo North Star Resources, Inc., owner of the Sarfartoq rare earth project in southwest Greenland. The project covers approximately 687 square kilometers and is centered on a large carbonatite complex that hosts rare earth mineralization. Its most advanced area, the ST1 Zone, contains a legacy NI 43-101 compliant Preliminary Economic Assessment-stage Mineral Resource estimate of 5.9 million tonnes of Indicated resources grading 1.8% total rare earth oxides (“TREO”), supported by extensive drilling, metallurgical testing, engineering studies and environmental work.

Sarfartoq is focused on magnet rare earth elements including neodymium and praseodymium, which are used in permanent magnets for electric vehicles, wind turbines, defense systems and other advanced technologies. Greenland Mines has highlighted the project’s infrastructure advantages, ongoing environmental studies and development potential, while an associated agreement with Neo Performance Materials provides offtake rights covering up to 60% of future production following completion of the acquisition.

Biotech

In addition to its mining activities, Greenland Mines operates a biotechnology division that includes KLTO-202, a gene therapy candidate with a primary indication for amyotrophic lateral sclerosis (“ALS”). The division is focused on developing biologic, cell and gene therapies targeting neurodegenerative and age-related disorders and is pursuing opportunities to advance and expand its therapeutic portfolio.

Market Opportunity

Rare earth elements and platinum group metals play important roles across industrial, energy, transportation and defense markets. Neodymium and praseodymium are key components in permanent magnets used in electric vehicles, wind turbines, robotics and high-efficiency motors, while palladium and platinum support a range of industrial and technology-related applications. As governments and manufacturers seek to strengthen access to strategic materials, critical minerals have become an increasing focus of industrial development and supply-chain planning.

Global demand for rare earth elements is projected to increase from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035, according to McKinsey & Company. The global rare earth elements market, valued at approximately $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030, according to Grand View Research. These trends are being driven by growing demand from electrification, renewable energy and advanced manufacturing industries.

China currently controls a significant portion of global rare earth mining and processing capacity, contributing to efforts across North America and Europe to establish alternative critical minerals supply chains. Through the Skaergaard Project and the pending acquisition of the Sarfartoq Project, Greenland Mines is building exposure to platinum group metals and magnet rare earth elements while advancing its strategy to support a North Atlantic critical minerals corridor linking Greenlandic resources with downstream processing, logistics infrastructure and industrial markets.

Leadership Team

Dr. Joseph Sinkule, Founder, Chief Executive Officer, Director and Chairman of the Board, has more than 40 years of experience in drug, biologic and medical-device research, development and commercialization. He has successfully managed multiple products through FDA approval and commercialization, founded numerous ventures and led financing, development and operational activities across pharmaceutical and biotechnology organizations. He also serves on corporate boards and advises investment firms and life sciences companies.

Jeffrey LeBlanc, Chief Financial Officer, brings more than two decades of experience in financial management, investing, advisory services and entrepreneurship. He is the co-founder of Winvest Acquisition Corp. and previously founded Out of Print, which was acquired by Penguin Random House in 2017. His prior experience includes investment roles at Greenlight Capital and GE Capital, as well as consulting work at McKinsey & Company. He holds an MBA from Harvard Business School and a Bachelor of Science in Chemical Engineering from MIT.

Dr. Bo Møller Stensgaard, President, has more than 20 years of experience in mineral exploration and natural resource development across Europe and the Arctic. A geologist with a PhD in economic geology, he previously served as a Senior Research Scientist at the Geological Survey of Denmark and Greenland and has led both public and private resource companies. His experience includes project advancement, permitting, environmental and social impact assessments, stakeholder engagement, investor relations and strategic advisory work related to European raw materials policy and funding.

For more information, visit the company’s website at https://greenlandmines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, recently received the delivery of a propane-fired tilting furnace at its Montauban Project to support on-site melting and casting of gold and silver into doré bars
• The furnace will form part of the company’s planned circuit for recovering precious metals from permitted tailings material and is a crucial milestone as the company moves to operationalize the facility
• ESGold has received – and continues to receive – infrastructure and equipment since April and continues to engage in activities that prepare the site for commissioning

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, recently took delivery of a propane-fired tilting furnace at its Montauban Gold-Silver Project in Quebec. The furnace, which features a hydraulic tilting system, supporting crucibles, and thermocouple temperature monitoring, can safely hold and melt up to 150 kilograms of metal and handle temperatures up to 1300°C (https://ibn.fm/MKcGT).

The furnace will form part of ESGold’s specialized equipment for on-site melting and casting of gold and silver into doré bars once the site is operational. The company intends to use the furnace in connection with its planned precious metal recovery circuit, which includes the Merrill-Crowe process, a technique for separating or recovering gold and silver from cyanide-based solutions or permitted tailings material.

“The delivery of this furnace is another practical and visible milestone in our transition from construction toward operations at Montauban,” commented Gordon Robb, CEO of ESGold. “This unit is part of the infrastructure required to move mineral recovery to doré production, and it reflects the steady progress being made across the project,” he added.

The furnace delivery marks another significant milestone as the company continues to advance the Montauban property toward commissioning and production. In addition to the furnace, the company has also received the Humphrey spirals and shaker tables, which collectively form part of Montauban’s gravity recovery circuit. The arrival of these major components at Montauban, Robb stated, allows investors to see “the processing infrastructure continuing to come together as we advance toward commissioning.” According to Robb, the continued delivery of the processing infrastructure, as well as advancements in site preparations, enable the company to build the “operational foundation required to bring Montauban into its next stage.”

ESGold is currently installing and integrating key processing equipment, developing the on-site precious metals handling infrastructure, and preparing the gold room and other supporting operational systems. In addition, the company is advancing, on a continued basis, its Montauban exploration model, which, according to the announcement, includes “ongoing integration of geological, geophysical, and historical datasets to support future exploration targets across the district.”

Covering approximately 244 square kilometers and home to 485 claims, the Montauban Project is being advanced to recover gold, silver, and mica from fully permitted historic mine tailings in the near term, with the company intending to commence gold and silver operations this year. In addition, ESGold is advancing district-scale exploration potential across the surrounding Montauban mining camp to feed its long-term strategy. The company is fully funded to commission the gold and silver operations and has completed the construction of a mill capable of processing up to 1,000 tons of precious metal per day (https://ibn.fm/XHQRh).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs.
• By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs.
• Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment.

The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.

This shift is helping fuel rapid growth in the nanomedicine and advanced drug-delivery sector, which is projected to reach approximately $410 billion by 2030. Rather than starting from scratch, nanomedicine seeks to enhance the performance of proven therapeutic compounds by improving their stability, targeting capabilities and overall effectiveness.

The opportunity is particularly compelling in oncology. Many cancer therapies are administered orally, a route that can present several challenges including poor bioavailability, inconsistent pharmacokinetics, limited tumor penetration and the potential for treatment resistance. Even highly effective compounds can see their therapeutic potential constrained by these delivery limitations.

Nanotechnology-based delivery systems are designed to overcome many of these obstacles. By improving how drugs are absorbed, distributed and delivered to tumor sites, researchers hope to increase efficacy while reducing unwanted side effects and treatment variability.

One company pursuing this strategy is Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on developing novel oncology solutions. The company’s proprietary Deciparticle(TM) platform utilizes nanoparticle engineering to reformulate hydrophobic drugs into intravenously administered nanoparticle therapies designed to improve delivery performance.

A key example is Sapu003, Oncotelic’s intravenous nanoparticle formulation of Everolimus, a widely used oncology drug. According to the company, the reformulation is designed to achieve near-complete bioavailability while improving tumor targeting and reducing toxicity. Oncotelic believes these improvements may help shift treatment outcomes beyond simply slowing tumor growth and toward more effective cancer cell destruction.

The potential implications extend beyond clinical performance. Successfully enhancing the delivery of existing drugs may create opportunities to extend product utility, improve patient outcomes and generate additional commercial value from compounds that have already demonstrated therapeutic relevance.

As interest in precision medicine and targeted oncology continues to grow, drug delivery technologies are increasingly being viewed as more than supporting tools. Instead, they are emerging as a critical layer of innovation that may help unlock the next generation of value creation in cancer therapeutics. For companies like Oncotelic Therapeutics, the ability to optimize how drugs reach and interact with tumors could prove just as important as discovering entirely new compounds.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC